Publications by authors named "Cindy Ursule-Dufait"
Donor-derived cell-free DNA (dd-cfDNA) is an emerging non-invasive biomarker for allograft injury detection. This study aimed to evaluate a new, decentralized dd-cfDNA testing kit against a centralized dd-cfDNA testing service broadly utilized in the United States. Kidney transplant recipients with decentralized and centralized dd-cfDNA measurements and concomitant kidney allograft biopsies were included in the study.
View Article and Find Full Text PDFBackground: In kidney transplantation, molecular diagnostics may be a valuable approach to improve the precision of the diagnosis. Using next-generation sequencing (NGS), we aimed to identify clinically relevant archetypes.
Methods: We conducted an Illumina bulk RNA sequencing on 770 kidney biopsies (540 kidney recipients) collected between 2006 and 2021 from 11 European centers.
Article Synopsis
- There is increasing interest in analyzing kidney biopsies through transcriptomic assessments to understand gene expression changes related to rejection.
- This study used next-generation sequencing (NGS) on RNA from 770 kidney biopsies to identify differentially expressed genes (DEGs) associated with antibody-mediated rejection (AMR) and T cell-mediated rejection (TCMR), revealing 603 and 1,186 new specific genes, respectively.
- Pathway analysis linked established panels to immunological processes in AMR and TCMR, while NGS uncovered novel transcripts that could inform future drug design and therapeutic strategies.
Article Synopsis
- Donor-derived cell-free DNA (dd-cfDNA) is an innovative noninvasive biomarker being studied for its ability to detect kidney allograft injuries, such as rejection.
- In a study involving 2,882 kidney transplant recipients, high levels of dd-cfDNA were strongly linked to various types of allograft rejection, and it significantly improved prediction models beyond what's typically used in patient monitoring.
- The study, which included diverse cohorts, reinforced that measuring dd-cfDNA could enhance the detection of even subtle rejection in stable patients, providing valuable insights for better transplant management.